Evogene (TSE:EVGN – Get Free Report) had its price target cut by research analysts at Ventum Financial from C$4.00 to C$3.00 in a report issued on Friday,BayStreet.CA reports.
Evogene Stock Performance
Evogene Company Profile
Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and guide the development of life-science products based on microbes, small molecules and genetic elements.
Recommended Stories
- Five stocks we like better than Evogene
- The Significance of Brokerage Rankings in Stock Selection
- Tesla Investors Continue to Profit From the Trump Trade
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- How to Evaluate a Stock Before Buying
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
